JP2022527638A5 - - Google Patents

Info

Publication number
JP2022527638A5
JP2022527638A5 JP2021560323A JP2021560323A JP2022527638A5 JP 2022527638 A5 JP2022527638 A5 JP 2022527638A5 JP 2021560323 A JP2021560323 A JP 2021560323A JP 2021560323 A JP2021560323 A JP 2021560323A JP 2022527638 A5 JP2022527638 A5 JP 2022527638A5
Authority
JP
Japan
Prior art keywords
composition according
composition
salt
phospholipid
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021560323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527638A (ja
JP7583741B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025246 external-priority patent/WO2020205530A1/en
Publication of JP2022527638A publication Critical patent/JP2022527638A/ja
Publication of JP2022527638A5 publication Critical patent/JP2022527638A5/ja
Application granted granted Critical
Publication of JP7583741B2 publication Critical patent/JP7583741B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021560323A 2019-03-29 2020-03-27 リポソーム製剤、ならびにリポソーム製剤を使用および調製する方法 Active JP7583741B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826874P 2019-03-29 2019-03-29
US62/826,874 2019-03-29
PCT/US2020/025246 WO2020205530A1 (en) 2019-03-29 2020-03-27 Liposomal formulations, and methods of using and preparing thereof

Publications (3)

Publication Number Publication Date
JP2022527638A JP2022527638A (ja) 2022-06-02
JP2022527638A5 true JP2022527638A5 (enExample) 2023-04-03
JP7583741B2 JP7583741B2 (ja) 2024-11-14

Family

ID=72666933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560323A Active JP7583741B2 (ja) 2019-03-29 2020-03-27 リポソーム製剤、ならびにリポソーム製剤を使用および調製する方法

Country Status (19)

Country Link
US (1) US20220184107A1 (enExample)
EP (1) EP3946365A4 (enExample)
JP (1) JP7583741B2 (enExample)
KR (1) KR20210143906A (enExample)
CN (1) CN113873998A (enExample)
AR (1) AR119705A1 (enExample)
AU (1) AU2020252005B2 (enExample)
BR (1) BR112021019593A2 (enExample)
CA (1) CA3134828A1 (enExample)
CL (1) CL2021002512A1 (enExample)
CO (1) CO2021014274A2 (enExample)
EA (1) EA202192663A1 (enExample)
IL (1) IL286713B2 (enExample)
MX (1) MX2021011876A (enExample)
PE (1) PE20212366A1 (enExample)
PH (1) PH12021552428A1 (enExample)
SG (1) SG11202110623PA (enExample)
TW (1) TWI906214B (enExample)
WO (1) WO2020205530A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205628A1 (en) * 2022-04-18 2023-10-26 City Of Hope Lipid nanoparticles, nucleic acids, and methods of use
TW202543582A (zh) * 2024-02-29 2025-11-16 美商葛里柯麥公司 脂質體調配物及其使用及製備方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156783B1 (en) * 1999-03-02 2007-10-24 Transave, Inc. Encapsulation of bioactive complexes in liposomes
US7060291B1 (en) * 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
WO2002076428A1 (en) * 2001-03-26 2002-10-03 Alza Corporation Liposome composition for improved intracellular delivery of a therapeutic agent
AU2003205048B2 (en) * 2002-01-09 2009-02-26 Transave, Inc. Efficient liposomal encapsulation
WO2003059322A1 (en) * 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
WO2010130896A2 (fr) * 2009-05-14 2010-11-18 Sanofi Pasteur Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif
MX366055B (es) 2011-08-31 2019-06-26 Novartis Ag Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
CA2890725A1 (en) 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
DK3954360T3 (da) * 2013-09-16 2025-05-12 Glycomine Inc Farmaceutisk præparat af kulhydrater til terapeutisk anvendelse
JP2017537650A (ja) 2014-10-09 2017-12-21 ライポテック・ピーティーワイ・リミテッド キメラタンパク質
US20170165374A1 (en) * 2015-11-18 2017-06-15 Insmed, Inc. Compositions and methods for treating bacterial infections

Similar Documents

Publication Publication Date Title
US20110097386A1 (en) Stabilized glucagon solutions
US20110237510A1 (en) Stabilized glucagon solutions
CN102630175B (zh) Spla2可水解脂质体的医药用途
JP2017522345A (ja) 非晶質炭酸カルシウムの液体および半固体の非水性製剤
JP2014519493A (ja) ポリマー共役脂質を含むリポソームおよび関連用途
JP2022527638A5 (enExample)
RU2013105783A (ru) Парентеральные составы производных элацитарабина
JP2008534525A (ja) リン脂質のポリエチレングリコール誘導体に包み込まれたアンスラサイクリン系抗腫瘍抗生物質のナノミセル製剤
JPWO2014025042A1 (ja) 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
KR100520738B1 (ko) 간염 치료제
US8241663B2 (en) Liposome preparation
WO2019082139A1 (en) LIPOSOMAL FINGOLIMOD HYDROCHLORIDE INJECTION
JPWO2005021012A1 (ja) ゲムシタビン封入薬剤担体
JP2009530318A (ja) 加水分解時に分子内環化反応を行うホスホリパーゼａ２分解性脂質を含む脂質ベース薬剤送達系
KR101971451B1 (ko) ２―하이드록시올레산이 포함된 지질 비히클의 용도
TW202143978A (zh) 格列本脲脂質體組合物及其製備方法
JP2025506429A5 (enExample)
EP1594488B1 (en) Stabilized pharmaceutical compositions of safingol and methods of using the same
TH2101006052A (th) สูตรผสมไลโปโซม, และวิธีการใช้และการเตรียมของสิ่งดังกล่าว
JPH04356421A (ja) プロスタグランジン類含有脂肪小体組成物
EP4667475A1 (en) Ph-responsive phospholipid
EP4346766A1 (en) Methods of treating or preventing allergies and chronic nasal congestion
CN101014322A (zh) 盐水中富含固醇的添加两性霉素的混合层状脂质体及其制备方法
JPWO2024171859A5 (ja) ｐＨ応答性リン脂質、リン脂質塩、脂質粒子、アルコール溶液、医薬、及び脂質粒子の製造方法
US20250228902A1 (en) Combination drug for treating malignant tumor